Personalis Strengthens Commercial Team with the Appointment of New Head of Population Genomics
16 9월 2020 - 5:01AM
Business Wire
Number of whole genomes sequenced surpasses 87,000, targeting
100,000 by year end
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for population sequencing and cancer, today announced the
appointment of Kevin Dunne as its new Head of Population
Genomics.
Mr. Dunne brings an extraordinarily relevant background to this
role. After studying at Oxford University, he worked in research at
the Wellcome Trust Centre for Human Genetics which had been
recently established at Oxford. He focused on technologies for
high-throughput genomics, a theme which has continued through his
career. From there he has spent over 25 years in roles of
increasing commercial responsibility at the intersection of
high-throughput genomic technologies, pharma and diagnostics. He
was involved in early planning for the Genomics England effort to
sequence 100,000 human genomes in the UK.
Prior to joining Personalis, Mr. Dunne was VP, Head of Clinical
Partnerships and Business Development at Genomics Medicine Ireland
(GMI), a division of WuXi NextCODE (now Genuity Science). GMI was
founded in 2015 and in 2018 secured funding of $400M to sequence
genomes of 400,000 people in Ireland. Mr. Dunne then moved into the
role of VP, Head of Disease Cohort Commercialization, which enabled
GMI to engage actively with pharmaceutical companies in the drug
discovery space, adding to a collaboration with AbbVie which Mr.
Dunne managed.
“We anticipate that population genomics efforts will
increasingly integrate healthcare systems with academic and
pharmaceutical research and include both inherited disease risk and
the management of cancer. Kevin brings a great background to enable
this collaborative vision of the future," said John West,
Personalis CEO.
Personalis also announced today that it has been able to
continue laboratory operations in spite of the on-going COVID-19
pandemic, and has now delivered over 87,000 genomes to date for the
U.S. Department of Veterans Affairs Million Veteran Program (VA
MVP). The company has received over 100,000 samples to date, and
continues to receive samples from the MVP.
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer
genomics, with a focus on data, scale, efficiency and quality.
Personalis operates one of the largest sequencing operations
globally and is currently the sole sequencing provider to the VA
MVP. In oncology, Personalis is transforming the development of
next-generation therapies by providing more comprehensive molecular
data about each patient’s cancer and immune response. The
Personalis® ImmunoID NeXT Platform® is designed to adapt to the
complex and evolving understanding of cancer, providing its
biopharmaceutical customers with information on all of the
approximately 20,000 human genes, together with the immune system,
from a single tissue sample. The Personalis Clinical Laboratory is
GxP-aligned as well as CLIA’88-certified and CAP-accredited. For
more information, please visit www.personalis.com and follow
Personalis on Twitter (@PersonalisInc).
Forward-Looking Statements
This press release contains or may imply "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements include all statements that are not
historical facts, including, for example, statements relating to
the potential advancement of or growth opportunities for
Personalis’ business, expansion of Personalis’ market presence in
population genomics and immuno-oncology, the company’s services for
the VA MVP, continued laboratory operations, the expected
completion date for sequencing 100,000 samples, and other future
events. These forward-looking statements are subject to risks and
uncertainties, including those related to population sequencing and
cancer genomics, market adoption of our services, our expectations
regarding future performance, and the COVID-19 pandemic, as well as
other risks and uncertainties discussed in Personalis’ filings with
the Securities and Exchange Commission, including in the “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” sections of the Company’s most
recently filed periodic reports on Forms 10-K and 10-Q and
subsequent filings and in the documents incorporated by reference
therein, all of which may significantly impact our business and
operations, the business and operations of our customers, our
ability to access capital and the value of our common stock. Except
as otherwise required by law, Personalis disclaims any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date hereof, whether as a result of new
information, future events or circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200915006268/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com 415-202-5678 Media Contact for
Personalis: Jennifer Havlek pr@personalis.com
www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024